GRAL
GRAIL Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth -6.2% ·
share flow +0.4% ·
net new positions -6.7%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 110 | +3 | 19.61M | $1.34B | +13 | −10 |
| Q1 2026 | 110 | -6 | 18.56M | $959.35M | +4 | −11 |
| Q4 2025 | 117 | +2 | 17.78M | $1.52B | +3 | n/a |
| Q3 2025 | 18 | +1 | 10.99M | $649.07M | +2 | −2 |
| Q2 2025 | 15 | -1 | 10.50M | $537.63M | +1 | −2 |
| Q1 2025 | 13 | +1 | 6.08M | $155.14M | +2 | −1 |
| Q4 2024 | 12 | +2 | 5.32M | $94.90M | +3 | −1 |
| Q3 2024 | 9 | -6 | 3.74M | $51.49M | n/a | −6 |
| Q2 2024 | 15 | n/a | 4.39M | $67.54M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 2.45M | n/a | $125.86M | 0.0% | n/c | 1 | SEC ↗ ×17 |
| 2 | PRIMECAP Management ✦ | 2.05M | +0.1% | $105.63M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 3 | The Vanguard Group ✦ (passive) | 1.90M | n/a | $97.82M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 4 | AQR Capital Management ✦ | 1.33M | -0.5% | $65.96M | 0.1% | ▼ Trim | 5 | SEC ↗ ×5 |
| 5 | State Street Global Advisors ✦ (passive) | 1.25M | -1.6% | $64.14M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 757.77K | +60.4% | $38.97M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 7 | Two Sigma Investments ✦ | 253.62K | -4.7% | $13.04M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | Renaissance Technologies ✦ | 153.50K | New | $7.89M | 0.0% | New | 1 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 135.91K | -49.3% | $6.99M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 10 | Millennium Management ✦ | 106.85K | -29.5% | $5.49M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 11 | GAMCO Investors ✦ | 29.71K | +6.1% | $1.53M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 29.43K | +15.8% | $1.51M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 13 | Fidelity (FMR) ✦ | 27.53K | n/a | $1.42M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 14 | Norges Bank ✦ (passive) | 21.60K | 0.0% | $1.11M | 0.0% | Held | 5 | SEC ↗ |
| 15 | Marshall Wace ✦ | 5.06K | -68.8% | $259,980 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Renaissance Technologies | $7.89M | 0.0% |
Exited
| Citadel Advisors | $3.91M | was 0.0% |
| Wellington Management | $551,919 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 9.40K shares, $485 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 6.03K sh · $830,465
Officer, Director · 7.05K sh · $964,946
Officer, Director · 2.11K sh · $293,394
Officer, Director · 400 sh · $53,247
Officer, Director · 1.00K sh · $134,384
Officer, Director · 3.40K sh · $460,508
Officer · 23.62K sh · $3.46M
Officer · 7.87K sh · $1.15M
Officer, Director · 10.00K sh · $1.10M
Officer, Director · 2.10K sh · $211,429
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology